Growth hormone receptor antagonist improves insulin resistance in acromegaly

Nabarro, 1993, Acromegaly, Clin. Endocrinol., 26, 481, 10.1111/j.1365-2265.1987.tb00805.x Ezzat, 1994, Acromegaly: clinical and biochemical features in 500 patients, Medicine, 73, 233, 10.1097/00005792-199409000-00001 Ho, 1992, Impact of octerotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly, Clin. Endocrinol., 36, 271, 10.1111/j.1365-2265.1992.tb01443.x Kasayama, 2000, Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients, Clin. Endocrinol., 52, 549, 10.1046/j.1365-2265.2000.00986.x Wasada, 1997, Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenectomy, Endocr. J., 44, 617, 10.1507/endocrj.44.617 Koop, 1994, Effect of octerotide on glucose tolerance in acromegaly, Eur. J. Endocrinol., 130, 581, 10.1530/eje.0.1300581 Seminara, 1998, Effect of long-term GH treatment on carbohydrate metabolism in children with GH deficiency, Clin. Endocrinol., 49, 125, 10.1046/j.1365-2265.1998.00502.x Rosenfalck, 2000, The effect of 30 months of low-dose replacement therapy with recombinant human GH (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults, J. Clin. Endocrinol. Metab., 85, 4173, 10.1210/jc.85.11.4173 Hussain, 1993, Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans, J. Clin. Invest., 92, 2249, 10.1172/JCI116828 Moses, 1996, Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in Type II diabetes, Diabetes, 45, 95, 10.2337/diabetes.45.1.91 Clemmons, 2000, The combination of insulin-like growth factor-I and insulin-like growth factor binding protein-3 reduces insulin requirements in type 1 diabetes: evidence for in vivo biologic activity, J. Clin. Endocrinol., 85, 1518, 10.1210/jc.85.4.1518 Trainer, 2000, Treatment of acromegaly with GH receptor antagonist Pegvisomant, NEJM, 1171, 10.1056/NEJM200004203421604 Herman-Bonert, 2000, Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs, J. Clin. Endocrinol. Metab., 85, 2958, 10.1210/jc.85.8.2958 Fuh, 1992, Rational design of potent antagonists to the human growth hormone receptor, Science, 256, 1677, 10.1126/science.256.5064.1677 Garcia-Estevez, 1998, Non-insulin-mediated glucose uptake in several insulin-resistant states in the postabsortive period, Diabetes Res. Clin. Pract., 39, 107, 10.1016/S0168-8227(97)00124-1 Dominici, 1999, Loss of sensitivity to insulin at easly events of the insulin signaling pathway in the liver of growth hormone-transgenic mice, J. Endocr., 161, 383, 10.1677/joe.0.1610383 Costa, 1998, Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus, FASEB J., 12, 1455, 10.1096/fasebj.12.14.1455 Hansen, 1986, Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action, Am. J. Physiol., 250, E269 Foss, 1991, Peripheral glucose metabolism in acromegaly, J. Clin. Endocrinol. Metab., 72, 1048, 10.1210/jcem-72-5-1048 Chen, 1995, Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice, Endocrinol, 136, 660, 10.1210/en.136.2.660 Rau, 1993, Bromocriptine treatment over12 years in acromegaly: effect on glucose tolerance and insulin secretion, Clin. Invest., 71, 372, 10.1007/BF00186626 Kirkegaard, 1990, Effect of one year of continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus, Acta Endocrinol., 122, 766, 10.1530/acta.0.1220766 Van der Lely, 2001, Long term treatment of acromegaly with Pegvisomant, a growth hormone receptor antagonist, Lancet, 358, 1754, 10.1016/S0140-6736(01)06844-1 Quattrin, 1997, Dual homronal replacement with insulin and insulin-like growth factorI in IDDM. Effects on glycemic control, IGFI levels, and safety profile, Diabetes Care, 20, 374380, 10.2337/diacare.20.3.374 O’Connell T, Clemmons DR. IGF-I/IGFBP-3 combination improves insulin resistance by GH dependent and independent mechanisms. J Clin Endocrinol Metab, in press